Answers are grounded in this paper and cite their sources.
Introduction Excessive fructose consumption is a significant driver of metabolic disorders, including obesity, diabetes, non-alcoholic fatty liver disease and non-alcoholic steatohepatitis primarily by promoting insulin resistance and fat accumulation. Ketohexokinase C (KHK-C), a pivotal enzyme in fructose metabolism, catalyzes the phosphorylation of fructose to fructose-1-phosphate, initiating a cascade of downstream metabolic processes. In contrast to glucose metabolism, KHK-C lacks negative feedback regulation, allowing the continuous phosphorylation of fructose, which leads to heightened levels of glucose, glycogen, and triglycerides in the bloodstream and liver. While targeting KHK-C offers a promising therapeutic avenue, no drugs have yet been approved for clinical use. Pfizer’s PF-06835919 has progressed to phase II trials, demonstrating a reduction in liver fat and improved insulin sensitivity, while Eli Lilly’s LY-3522348 also shows significant potential. Nonetheless, there remains a critical need for the development of novel KHK-C inhibitors that offer improved pharmacokinetics, enhanced efficacy, and superior safety profiles. Methods In the present study, a comprehensive computational strategy was employed to screen 460,000 compounds from the National Cancer Institute library for potential KHK-C inhibitors. Initially, pharmacophore-based virtual screening was used to identify potential hits, followed by multi-level molecular docking, binding free energy estimation, pharmacokinetic analysis, and molecular dynamics (MD) simulations to further evaluate the compounds. This multi-step approach aimed to identify compounds with strong binding affinity, favorable pharmacokinetic profiles, and high potential for efficacy as KHK-C inhibitors. Results Ten compounds exhibited docking scores ranging from −7.79 to −9.10 kcal/mol, surpassing those of the compounds currently undergoing clinical trials, PF-06835919 (−7.768 kcal/mol) and LY-3522348 (−6.54 kcal/mol). Their calculated binding free energies ranged from −57.06 to −70.69 kcal/mol, further demonstrating their superiority over PF-06835919 (−56.71 kcal/mol) and LY-3522348 (−45.15 kcal/mol). ADMET profiling refined the selection to five compounds ( 1 , 2, and 4–6 ), and molecular dynamics simulations identified compound 2 as the most stable and promising candidate compared to the clinical candidate PF-06835919. Conclusion These findings highlight compound 2 as a potent KHK-C inhibitor with predicted pharmacokinetics and toxicity profiles supporting its potential for treating fructose-driven metabolic disorders, warranting further validation.
No takes yet. Share an insight, caveat, or question.
Elsaman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: